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Acute myeloid leukemia is a disease of the elderly (median age atdiagnosis, 65-70 years). The prognosis of older acute myeloidleukemia patients is generally poor. While genetic markers have
become important tools for risk stratification and treatment selection in
young and middle-aged patients, their applicability in very old patients
is less clear. We sought to validate existing genetic risk classification sys-
tems and identify additional factors associated with outcomes in inten-
sively treated patients aged ≥75 years. In 151 patients who received
induction chemotherapy in the AMLCG-1999 trial, we investigated
recurrently mutated genes using a targeted sequencing assay covering 64
genes. The median number of mutated genes per patient was four. The
most commonly mutated genes were TET2 (42%), DNMT3A (35%),
NPM1 (32%), SRSF2 (25%) and ASXL1 (21%). The complete remission
rate was 44% and the 3-year survival was 21% for the entire cohort.
While adverse-risk cytogenetics (MRC classification) were associated
with shorter overall survival (P=0.001), NPM1 and FLT3-ITD mutations
(present in 18%) did not have a significant impact on overall survival.
Notably, none of the 13 IDH1-mutated patients (9%) reached complete
remission. Consequently, the overall survival of this subgroup was sig-
nificantly shorter than that of IDH1-wildtype patients (P<0.001). In sum-
mary, even among very old, intensively treated, acute myeloid leukemia
patients, adverse-risk cytogenetics predict inferior survival. The spec-
trum and relevance of driver gene mutations in elderly patients differs
from that in younger patients. Our data implicate IDH1 mutations as a
novel marker for chemorefractory disease and inferior prognosis.
(AMLCG-1999 trial: clinicaltrials.gov identifier, NCT00266136)
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ABSTRACT
Introduction
The incidence of acute myeloid leukemia (AML) is highest among the elderly,
with the median age at diagnosis being around 70 years.1 The prognosis of older
AML patients is generally considered poor. In this age group, comorbidities, poor
performance status and a reluctance of physicians and patients to use treatment
regimens perceived as toxic often lead to the decision to avoid induction
chemotherapy in favor of less intensive therapies.2-6 On the other hand, data from
patient registries and randomized trials suggest that intensive induction therapy
can result in prolonged overall survival (OS), at least in a
subset of elderly patients aged 70-79 years, and may even
be beneficial in selected octogenarians.4,7-10 However, it
remains unclear which genetic and clinical factors are rel-
evant to identify those elderly patients most likely to ben-
efit from, and least likely to be harmed by, induction
chemotherapy.11
Advances in the field of molecular genetics and the
development of next-generation sequencing expanded our
knowledge of recurrently mutated genes in AML and their
role in disease pathophysiology, and led to refined risk
classifications in younger patients.1,12,13 However, elderly
patients were underrepresented or excluded in these stud-
ies, and the question thus arises whether the spectrum
and prognostic relevance of gene mutations are similar in
very old AML patients. Some studies of established genet-
ic risk factors indicate that there may be important differ-
ences between elderly and younger patients.12,14,15 For
example, the FLT3-ITD mutation is a well-recognized
adverse prognostic factor in young adults, whereas its
impact is reduced or absent in elderly patients.1,7,14,16,17
Therefore, comprehensive genetic analyses in cohorts of
very old patients are needed to clarify the relevance of dis-
tinct gene alterations in this subset of patients. 
To identify prognostic factors associated with clinical
outcomes in elderly AML patients, we studied 151
patients aged ≥75 years who received intensive induction
therapy. The mutational spectrum in 64 recurrently mutat-
ed AML genes was analyzed by targeted next-generation
sequencing. We then studied associations of genetic alter-
ations with other known prognostic factors, patients’
characteristics, and outcomes. Our aim was to define sub-
sets of patients who may benefit from intensive induction
therapy. Furthermore, we evaluated the prognostic rele-
vance of the British Medical Research Council (MRC)
2010 and European LeukemiaNet (ELN) 2017 risk classifi-
cation schemes in this subset of patients.1,18
Methods
Patients, treatment, karyotype and molecular analyses
We studied 151 patients aged  ≥75 years with newly diagnosed
AML or high-risk myelodysplastic syndromes (10% - <20% bone
marrow blasts; n=3), diagnosed according to World Health
Organization criteria, who had suitable bone marrow or peripher-
al blood specimens for genetic analysis. All patients received inten-
sive induction treatment during the German AML Cooperative
Group AMLCG-1999 randomized, multicenter, phase III trial (clin-
icaltrials.gov identifier, NCT00266136) between 1999 and 2011.
Participants aged ≥60 years were randomized to receive a first
induction course with high-dose cytarabine and mitoxantrone
(HAM) or with standard-dose cytarabine, daunorubicin and 6-
thioguanine (TAD-9). A second HAM induction course was
administered from day 21 only if ≥5% residual blasts were present
in a bone marrow aspirate taken on day 15. Another cycle of
TAD-9 was given as consolidation therapy, followed by monthly
cytarabine-based maintenance chemotherapy (Online
Supplementary Data). Karyotype analyses were performed central-
ly and results were classified according to the 2010 MRC classifi-
cation.18 
Molecular analysis encompassed sequencing of 64 genes recur-
rently mutated in AML. We analyzed either known mutational
hotspots or the entire coding sequence using an amplicon-based
approach (Haloplex, Agilent, Boeblingen, Germany) as described
previously.12 The median sequencing coverage of the target region
across all samples was 520-fold, and 98.8% of the target region
was covered at >30-fold. Gene alterations with variant allele fre-
quencies of ≥2% were classified as driver mutations, variants of
unknown significance or germline polymorphisms.12 The
Catalogue Of Somatic Mutations In Cancer (COSMIC), The
Cancer Genome Atlas (TCGA) and the Single Nucleotide database
(dbSNP) served as databases to compare and classify the muta-
tional results.19-21 NPM1,22 FLT3-ITD23 and CEBPA24 mutations were
additionally tested using polymerase chain reaction followed by
Sanger sequencing and/or fragment analysis. 
Written informed consent for inclusion in the clinical trial and
genetic analyses was provided by all patients. All study protocols
were in accordance with the Declaration of Helsinki and approved
by the institutional review boards of each participating center.  
Statistical analysis
Associations among gene mutations, and between gene muta-
tions and patients’ pretreatment features, were analyzed using the
Fisher exact test for categorical variables and the Wilcoxon rank-
sum test for continuous variables. The Kaplan-Meier method was
used to calculate estimated survival probabilities, with the log-
rank test evaluating differences between survival distributions. A
multivariate Cox regression model including known risk factors
[MRC risk category and Eastern Cooperative Oncology Group
performance status (ECOG PS)], and gene mutations that showed
a univariate association with OS (at P<0.10), was used to identify
factors associated with survival. Statistical analyses were per-
formed using SPSS version 24.0 (Chicago, IL, USA). All statistical
tests are two-sided, and a P value of ≤0.05 was considered statis-
tically significant. 
Results
Patients’ characteristics
We identified 151 patients aged ≥75 years treated in the
AMLCG-1999 trial for whom suitable material for genetic
analyses was available. Details of this trial have been pub-
lished elsewhere.25 The patients’ baseline characteristics
are shown in Table 1. The median age of the subjects was
76 years (range, 75-86). Eighty-one percent of patients had
a clinical diagnosis of de novo AML, 15% had secondary
AML and 3% had therapy-related AML. Three patients
(2%) had high-risk myelodysplastic syndromes (10-<20%
bone marrow blasts). Most patients (90%) had an ECOG
PS of ≤2. Among 137 patients with cytogenetic data, 82%
belonged to the intermediate-risk group according to the
MRC 2010 classification, including 52% with cytogeneti-
cally normal AML. Only three patients (2%) had favorable
cytogenetics, and 16% fell in the MRC adverse-risk group. 
Treatment outcomes
In the overall cohort, the rates of complete remission
(CR) and CR with incomplete blood count recovery (CRi)
were 44% and 4%, respectively. The median event-free
survival (EFS) was 1.7 months. The median relapse-free
survival (RFS) for patients achieving a remission was 12
months, and the median OS was 6.0 months (Online
Supplementary Figure S1). The 3-year OS rate for the entire
study population was 21%, and survival was similar for
patients aged 75-79 or 80-86 years (P=0.3) (Online
Supplementary Figure S2A). Patients with an ECOG PS of 3
or 4 had shorter OS compared to patients with an ECOG
PS of 0-2 (P=0.036) (Online Supplementary Figure S2B),
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mostly because of an increased risk of early death within
60 days from starting treatment (26% for patients with an
ECOG PS of 0-1, 40% for those with a PS of 2, and 75%
for patients with an ECOG PS of 3 or 4). Patients random-
ized to HAM induction tended to have longer OS com-
pared to patients randomized to TAD induction (median
OS: TAD, 3.1 months versus HAM, 7.8 months; P=0.09)
(Online Supplementary Results and Online Supplementary
Figure S3). 
Impact of cytogenetics on survival
Since only three patients had favorable-risk cytogenetics
according to the MRC classification, the favorable- and
intermediate-risk groups were analyzed jointly. Patients in
the favorable- or intermediate-risk categories had a non-
significantly higher remission rate than adverse-risk
patients (CR/CRi, 51% versus 27%; P=0.2). The EFS, RFS,
and OS of favorable- and intermediate-risk patients were
significantly longer than those for adverse-risk patients
(EFS: P=0.001; RFS: P=0.006; OS: P=0.001) (Figure 1A and
Online Supplementary Figure S4). 
Gene mutations and patients’ pretreatment 
characteristics
We identified a total of 622 driver mutations affecting
64 genes, with a median number of four mutated genes
per patient (range, 1-10 mutations/patient) (Online
Supplementary Figure S5). Older age (81-86 years versus 75-
80 years) was not associated with a higher number of driv-
er gene mutations (P=0.5, data not shown). The most fre-
quently mutated genes in this age group were TET2
(63/151, 42%), DNMT3A (53/151, 35%), NPM1 (48/151,
32%), FLT3 (45/151, 30%), SRSF2 (38/151, 25%), ASXL1
(31/151, 21%), and RUNX1 (28/151, 19%) (Table 1, Figure
2A). Compared to previously studied patients aged <60 or
60-74 years12, those aged ≥75 years had a higher frequency
of TET2, SRSF2 and ASXL1 mutations. TP53 mutations
occurred in 14% of patients (21/151) and were strongly
associated with complex karyotypes (P<0.001). Eighty-
three percent of patients (126/151) harbored one or more
Genetics and outcomes in AML patients ≥75 years
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Table 1. Patients’ baseline characteristics.
Variable                                                                   Total cohort (n=151)
Age [years], median (range)                                                    76 (75 – 86)
Male sex                                                                                           81 (54%)
Disease type                                                                                             
De novo AML                                                                                122 (81%)
Secondary AML                                                                             22 (15%)
Therapy-related AML                                                                    4 (3%)
MDS (10%-<20% blasts)                                                              3 (2%)
ECOG performance statusa                                                                  
0                                                                                                        13 (10%)
1                                                                                                        70 (51%)
2                                                                                                        42 (31%)
≥3                                                                                                      12 (9%)
WBC [×109/L], median (range)                                           14.2 (0.1 – 318.1)
Blast count at diagnosis                                                                        
% bone marrow blasts, median (range)                             80 (10 – 100)
% peripheral blood blasts, median (range)                       26 (0 – 100)
MRC cytogenetic risk categoryb                                                           
Favorable                                                                                          3 (2%)
Intermediate                                                                                112 (82%)
Adverse                                                                                           22 (16%)
ELN 2017 genetic groupc
Favorable                                                                                        37 (28%)
Intermediate                                                                                 32 (24%)
Adverse                                                                                           65 (49%)
Remission status after induction                                                       
CR                                                                                                    66 (44%)
CRi                                                                                                     6 (4%)
Persistent AML                                                                             25 (17%)
Death during induction                                                               54 (35%)
Most commonly mutated genes                                                         
TET2                                                                                                63 (42%)
DNMT3A                                                                                         53 (35%)
NPM1                                                                                              48 (32%)
SRSF2                                                                                               38 (25%)
ASXL1                                                                                               31 (21%)
RUNX1                                                                                            28 (19%)
FLT3-ITD                                                                                         27 (18%)
NRAS                                                                                                25 (17%)
IDH2                                                                                                 23 (15%)
TP53                                                                                                 21 (14%)
FLT3-TKD                                                                                        18 (12%)
IDH1                                                                                                  13 (9%)
ECOG: Eastern Cooperative Oncology Group; WBC: white blood cell count; MRC:
British Medical Research Council; ELN: European LeukaemiaNet; CR: complete remis-
sion; CRi: complete remission with incomplete blood count recovery; ITD: internal
tandem duplication; TKD: tyrosine kinase domain. aNo data available for 14 patients;
bNo karyotype was available for 14 patients; cClassification was not possible for 17
patients due to lack of karyotype or FLT3-ITD allelic ratio.
Figure 1. Overall survival according to the MRC and ELN risk classifications. (A)
Overall survival for patients in the favorable- and intermediate-risk groups (green)
compared to the adverse-risk group (red) according to the MRC cytogenetic risk cat-
egory. (B) Overall survival for patients in the favorable-(green), intermediate-
(orange) and adverse-risk groups (red) according to the ELN 2017 genetic category. 
B
A
mutations in TET2, DNMT3A, SRSF2, ASXL1, TP53 or
SF3B1 - genes known to be involved in age-associated
clonal hematopoiesis (Figure 2B).26,27 RUNX1 mutations
were positively associated with mutations in SRSF2 and
ASXL1 (SRSF2, P=0.02; ASXL1, P=0.01), while ASXL1 and
DNMT3A mutations were inversely correlated with each
other (P=0.003). NPM1 mutations were mutually exclu-
sive with RUNX1 mutations, and only two patients had
co-mutations in NPM1 and ASXL1 (P<0.001) (Figure 2B).
Association between gene mutations, therapy
response and survival 
The number of mutated genes per patient was not asso-
ciated with OS in a comparison of patients with one to
three (62/151, 41%), four to seven (80/151, 53%) or eight
to ten (9/151, 6%) mutated genes (P=0.6) (Online
Supplementary Figure S6). 
Univariate analyses of the associations between the
most common gene mutations and CR rate and OS are
shown in Online Supplementary Table S1.  NPM1 muta-
tions, which have been shown to be associated with a
higher CR rate in younger AML patients, were not associ-
ated with response to induction treatment in our cohort.
Patients with NPM1 mutations had a significant longer
EFS (P=0.027) (Online Supplementary Figure S7A) and tend-
ed to have a longer RFS (P=0.081) (Online Supplementary
Figure S7B) and OS (P=0.090) (Figure 3A) than wildtype
patients. Among patients who achieved CR, those with
mutated NPM1 had a significantly longer OS (calculated
from the day of achieving CR) than NPM1-wildtype
patients (P=0.037) (Online Supplementary Figure S7C).
Within the subgroup of patients with cytogenetically nor-
mal AML, there was no difference in OS between NPM1-
mutated and -wildtype patients (P=0.4, data not shown).
Likewise, the OS of NPM1mutated/FLT3-ITDwildtype patients - a
known favorable-risk subgroup, at least in younger
patients - was similar to that of the rest of the cohort
(P=0.59) (Figure 3B). 
FLT3-ITD mutations had no impact on EFS, RFS, or OS
in the entire cohort [EFS: P=0.54 (Online Supplementary
Figure S8A); RFS: P=0.78 (Online Supplementary Figure S8B);
OS: P=0.32 (Figure 3C)] or in patients with cytogenetically
normal AML (P=0.26) (Online Supplementary Figure S8C).
Since the FLT3-ITD allelic ratio is an important prognosti-
cator recognized in the ELN 2017 classification, we also
explored its impact on OS. A high FLT3-ITD allelic ratio
(≥0.5) was not associated with a shorter OS compared to
a low allelic ratio (<0.5) or FLT3-ITD wildtype (OS:
P=0.53) (Online Supplementary Figure S8D). In the context
of co-mutated NPM1, there was also no impact on OS of
a high FLT3-ITD allelic ratio compared to a low allelic
ratio or to NPM1mutated/FLT3-ITDwildtype patients (OS: P=0.4)
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Figure 2. Genetic landscape of old acute myeloid leukemia patients. (A) Driver gene mutations in 151 AML patients ≥75 years of age at primary diagnosis. The bar
chart shows the 15 most commonly mutated genes in the 151 AML patients aged ≥75 years compared to 664 patients aged <60 and 60-74 at primary diagnosis
(data from Metzeler et al.12). (B) Heatmap showing associations between different driver gene mutations. Each column represents one patient.
B
A
(Online Supplementary Figure 7D). Patients with TP53muta-
tions showed trends towards shorter EFS (P=0.079)
(Online Supplementary Figure S9A) and OS (P=0.073) (Figure
3D), and had a significantly shorter RFS (P=0.041) (Online
Supplementary Figure S9B), compared to TP53-wildtype
patients. TP53-mutated patients who achieved CR had a
significantly shorter OS (calculated from the day of
achieving CR) compared to that of TP53-wildtype patients
in CR (P=0.005) (Online Supplementary Figure S9C).
IDH1 mutations: impact on event-free and overall 
survival, association with patients’ pretreatment 
characteristics and other gene mutations 
In our cohort of old AML patients, the only gene signif-
icantly associated with OS in univariate analysis was
IDH1 (Online Supplementary Table S1). None of the IDH1
codon R132-mutated patients (13/151, 9%) reached
CR/CRi (P<0.001). Consequently, IDH1-mutated patients
had a significantly shorter EFS (P<0.001) (Online
Supplementary Figure S10A) and OS (P≤0.001) Figure 4A)
than IDH1-wildtype patients. 
Within this elderly cohort of patients, IDH1-mutated
patients showed a trend towards older age (P=0.08)
(Online Supplementary Table S2). Furthermore, IDH1-
mutated patients tended to have higher platelet counts
(P=0.20) and lower WBC counts (P=0.10) than IDH1-wild-
type patients. There was no difference in peripheral blood
or bone marrow blast counts between IDH1-wildtype and
IDH1-mutated patients. IDH1 mutations were associated
with cytogenetically normal AML (P=0.069): 10/13 IDH1-
mutated patients had a normal karyotype, whereas one
patient had a 7q deletion, one had trisomy 8, and kary-
otype was unknown for one patient. Further information
on clinical characteristics of the 13 IDH1-mutated patients
are shown in Online Supplementary Table S3. IDH1 and
IDH2 mutations were mutually exclusive (P=0.2), and
IDH2 mutations, found in 15% of patients (23/151), had
no impact on OS (P=0.5). TET2 mutations were mutually
exclusive with IDH1 mutations (P=0.001), and with
mutated IDH2 (P=0.002).
Five IDH1-mutated patients also carried NPM1 muta-
tions. While patients with NPM1 mutations overall tend-
ed to have favorable OS (Figure 3A), IDH1 mutations had
a dominant negative prognostic effect even when co-
occurring with mutated NPM1 (Figure 4B). Four IDH1-
mutated patients had simultaneous FLT3-TKD mutations,
an association that almost reached statistical significance
(P=0.051). There was no association between IDH1 and
FLT3-ITD mutations (P=0.5). 
Multivariate analysis of prognostic factors in old,
intensively treated acute myeloid leukemia patients 
We used a multivariate Cox regression model to identify
the most relevant predictors of OS in this cohort of inten-
sively treated AML patients ≥75 years (Table 2). In this
multivariate model, using the MRC classification, ECOG
PS, and IDH1, NPM1 and TP53 mutations as covariates,
only IDH1 mutations and the MRC adverse cytogenetic
Genetics and outcomes in AML patients ≥75 years
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Figure 3. Overall survival according to gene mutations. (A) NPM1 mutations: overall survival in NPM1-mutated (green) compared to NPM1-wildtype patients (red). (B)
NPM1-mutated/FLT3-ITD-negative patients: overall survival in NPM1-mutated/FLT3-ITD-wildtype patients (green) compared to other patients (red). (C) FLT3-ITD muta-
tions: overall survival in FLT3-ITD-mutated (red) compared to FLT3-ITD-wildtype patients (green).  (D) TP53 mutations: overall survival in TP53-mutated patients (red)
compared to TP53-wildtype patients (green). “Mut” denotes mutated and “wt” wildtype.
B
D
A
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risk category had significant negative impacts on OS.
There was a trend towards worse OS for patients with
poor ECOG PS. 
Patients who were characterized by wildtype IDH1,
favorable or intermediate cytogenetics and an ECOG PS
of 0-2 had a significantly longer median OS than patients
who had at least one high-risk feature (mutated IDH1,
adverse cytogenetics, and/or performance status ≥3) (3-
year OS, 25% versus 5%; P<0.001) (Figure 5). 
Association between the European LeukemiaNet 2017
and Medical Research Council classifications 
and outcomes 
When we applied the novel ELN 2017 genetic risk clas-
sification to our cohort of very old patients, more patients
were assigned to the favorable- and adverse-risk cate-
gories, and fewer patients to the intermediate-risk group,
compared to the MRC classification (Table 1).
Surprisingly, patients classified as ELN-2017 intermediate-
risk had longer OS (median, 10.7 months) compared to
both the favorable- and adverse-risk groups (median, 3.4
months and 3.6 months, respectively; P=0.009) (Figure
1B). Furthermore, in the MRC adverse-risk subgroup, all
patients died within 2 years, whereas seven ELN-2017
adverse-risk patients survived for 3 years or longer. 
Discussion
Elderly AML patients are frequently underrepresented
in clinical trials evaluating induction chemotherapy sched-
ules, as well as in studies of the genetic basis of the dis-
ease.12,28-30 For example, the widely-used MRC cytogenetic
risk categories were derived from a cohort of patients aged
16-59 years.18 This selection bias contrasts with the epi-
demiology of AML, which is mostly a disease of elderly
patients. While many study groups have excluded older
patients from trials involving induction chemotherapy,
and less-intensive regimens, including the hypomethylat-
ing agents, decitabine and azacitidine, are now widely
used in this age group, some studies suggest that a sub-
group of old patients may benefit from induction
chemotherapy.7,8,10 There is, therefore, a vital need to iden-
tify factors that are associated with outcomes and that
could support therapeutic decision-making in this diffi-
cult-to-treat patient cohort. 
We designed our study to focus on a cohort of very old
patients (aged 75 years or older) included in a trial of
induction chemotherapy. In this age group, the benefits of
induction chemotherapy and potential clinical and genetic
markers for therapy success or failure are not well defined.
We found that, even among very old patients, favorable-
V.V. Prassek et al.
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Figure 5. Impact of Eastern Cooperative Oncology Group performance status,
Medical Research Council classification and IDH1mutations on overall survival.
Overall survival in patients with an ECOG performance status of 0-2, favorable or
intermediate MRC category and IDH1-wildtype compared to patients with an
ECOG performance status of 3-4 or MRC adverse category or IDH1 mutation.
Figure 4.  IDH1 mutations and survival. (A) Overall survival in IDH1-mutated
patients (red line) compared to IDH1-wildtype patients (green line). (B) Overall
survival in NPM1-mutated/IDH1-mutated patients (red line) compared to NPM1-
mutated/IDH1-wildtype patients (green line). Mut: mutated; wt: wildtype.
A
B
Table 2.  Multivariate analysis for overall survival.
Variable                                                        HR (95% CI)                P
MRC cytogenetic risk group                            2.21 (1.19 – 4.09)            0.012
(adverse vs. favorable/ intermediate)
NPM1-mutated                                                   0.97 (0.62 – 1.51)            0.889
TP53-mutated                                                      1.32 (0.69 – 2.49)            0.402
IDH1-mutated                                                     3.68 (1.87 – 7.23)           <0.001
ECOG performance status                             1.68 (0.89 – 3.18)            0.113
(3-4 vs. 0-2)                                                                         
HR: hazard ratio; CI: confidence interval; MRC: British Medical Research Council;
ECOG: Eastern Cooperative Oncology Group.
and intermediate-risk cytogenetics remain associated with
a relatively favorable OS in a comparison with adverse-
risk cytogenetics. This finding is in agreement with that of
a retrospective analysis by Heiblig and colleagues.31 In
their study, older age (≥75 years in a cohort with an age
range of 70-93 years) was also a strong prognostic factor in
terms of OS whereas according to our own data, higher
age (80-86 years versus 75-79 years) did not associate with
OS, potentially due to the fact that only very fit octagenar-
ians were enrolled in a trial of induction chemotherapy.
Patients in the cohort reported by Heiblig and colleagues
received three different treatment modalities: intensive
chemotherapy, less intensive treatment (i.e. low-dose
AraC, azacitidine or decitabine) or best supportive care
only.31 The median OS in patients aged ≥75 years, regard-
less of therapy type, was 4.3 months with a 3-year OS rate
of 14%, compared to a median OS of 10 months and a 3-
year OS rate of 20% in patients aged <75 years. In patients
≥75 years of age who all received intensive chemotherapy,
Heiblig and colleagues reported a 3-year OS rate of 24%,
which is comparable to the 3-year OS rate of 21% found
in our retrospective analysis. Importantly, the analysis by
Heiblig and colleagues also showed that long-term sur-
vival beyond 3 years was exceedingly rare in patients
treated with hypomethylating agents, while survival
times exceeding 10 years were observed in intensively
treated patients.
Our previous analysis of the mutational landscape in
664 intensively treated AML patients included 288
patients ≥60 years of age at primary diagnosis.12 We
reported that the mutational spectrum in older AML
patients differed from that in younger patients (<60 years).
In this study, we extend this finding to very old patients
aged ≥75 years. The five most frequently mutated genes
were TET2, DNMT3A, NPM1, SRSF2 and ASXL1.12 The
high incidence of TET2, DNMT3A, SRSF2, ASXL1, TP53
and SF3B1 mutations in our patients is in agreement with
reports showing that these genes are frequently mutated
in age-associated clonal hematopoiesis.26,32 Overall, 83%
(126/151) of AML patients ≥75 years carried at least one
mutation in one of these six genes. 
Recently, Baldus and colleagues published data on the
genetic and epigenetic landscape in 93 elderly AML
patients (65-90 years) enrolled in a Study Alliance
Leukemia (SAL) registry.33 Similar to our results, they iden-
tified a high frequency of mutations in DNMT3A, TET2,
SRSF2, ASXL1 and RUNX1. Strikingly, NPM1 mutations
were much less common (16.1% of patients) than in our
cohort (32%). This difference remains unexplained, since
there are no obvious differences regarding, for example,
the proportion of patients with de novo versus secondary
AML which could affect the frequency of NPM1 muta-
tions. 
We unexpectedly identified IDH1 mutations as the
strongest genetic predictor of shorter survival in this age
group. The prognostic value of IDH1 and IDH2 mutations
in AML has been studied by multiple groups but is still
controversial.34,35 While some analyses found no impact on
OS,36 others demonstrated associations with poor37-40 or
favorable prognosis.28 A recently published meta-analysis
of 33 studies found that IDH1 and IDH2 mutations, ana-
lyzed jointly, do not affect OS or EFS.34 IDH1 mutations,
when analyzed separately, are associated with lower CR
rates, shorter EFS and shorter OS. A negative impact of
IDH1 mutations on outcomes has also been described in
younger NPM1-mutated/FLT3-ITD-negative patients.37,39
These findings are generally compatible with the results of
our study. This meta-analysis also revealed that IDH2-
mutated patients had a longer OS than IDH2-wildtype
patients, while in our study there was no impact of IDH2
mutations on OS (P=0.53). This discrepancy may be
explained by our focus on very old AML patients, among
whom the prognostic relevance of gene mutations may
differ from that among younger patients. It remains
unclear why mutations in two related genes with appar-
ently similar functional consequences21,41,42 might have
varying or even opposite impacts on OS. The poor out-
come of old AML patients with mutated IDH1 needs to be
validated in additional cohorts. If the negative prognostic
effect of IDH1 mutations in old patients is confirmed in
other studies, these patients should not be considered can-
didates for induction chemotherapy. Targeted inhibitors
of the mutant IDH1 enzyme, which are currently being
tested in clinical trials, may become a preferred therapeu-
tic approach for these patients in the future.
In our multivariate analysis, results of cytogenetic analy-
sis (classified according to the MRC system) were a strong
predictor of outcomes. Compared to the MRC risk cate-
gories, application of the new ELN-2017 genetic risk clas-
sification led to an expansion of the favorable- and
adverse-risk categories (Table 1). The inclusion of RUNX1,
ASXL1 and TP53 mutations in the ELN adverse-risk cate-
gory, in particular, affects the risk classification of this
cohort of very old patients in whom these mutations are
common. Many patients who were classified as interme-
diate-risk based on cytogenetic results alone according to
the MRC recommendations are now re-classified into the
adverse-risk group. At least in our cohort, however, the
MRC cytogenetic risk classification appears to provide
better prognostic stratification compared to the ELN-2017
system. Thus, further validation of the ELN-2017 classifi-
cation in larger cohorts of elderly patients seems warrant-
ed to define its applicability in this age group.
Our finding that in patients aged 75 or older, the prog-
nosis of ELN-2017 favorable-risk patients was not better,
and may in fact be worse, than that of the intermediate-
risk group suggests that favorable molecular markers
established in younger patients (e.g., mutated NPM1
without or with a low FLT3-ITD allelic ratio, biallelic
CEBPA mutations) have weaker prognostic relevance in
elderly patients. Indeed, in our cohort, the NPM1-mutat-
ed/FLT3-ITD-negative genotype did not associate with
favorable outcomes. NPM1 mutations alone were associ-
ated with significantly longer EFS, but there were only
trends towards longer RFS and OS. Among patients who
achieved CR after induction therapy, those with mutated
NPM1 had a significantly longer OS, suggesting that these
patients might have benefited from cytarabine-based con-
solidation and prolonged monthly maintenance therapy as
used in the AML-CG 1999 trial. In contrast, the MRC
adverse-risk group, defined by cytogenetic alterations
only, had significantly shorter OS compared to the cytoge-
netic favorable- and intermediate-risk groups. In contrast
to the ELN-2017 adverse-risk group, no MRC adverse-risk
patient survived beyond 2.1 years. Thus, karyotype rather
than gene mutations appears to be the major factor defin-
ing the prognosis in very old, intensively treated AML
patients.43
One limitation of our study is that all patients were
treated with the same treatment modality - intensive
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chemotherapy. Consequently, we were unable to study
interactions between genetic alterations and type of treat-
ment (intensive versus not intensive) with regard to
patients’ outcomes. However, we found that patients ran-
domized to the more intensive induction regimen (HAM)
tended to have longer OS compared to those randomized
to TAD. While this non-significant difference may be due
to the play of chance, the finding that better outcomes
were observed in the more intensive arm supports the
conclusion that induction chemotherapy is tolerable for
selected patients in this age group. Two randomized phase
III trials in newly diagnosed AML patients aged ≥65 years
compared treatment with the hypomethylating agents,
azacitidine and decitabine, to alternative therapies (best
supportive care, low-dose cytarabine, or intensive
chemotherapy).44,45 The median OS of azacitidine-treated
patients was 10.4 months, and that of decitabine-treated
patients was 7.7 months, compared to a median OS of 6.0
months in our study. Obviously, these cohorts of patients
cannot be compared directly because of their different age
ranges and inclusion criteria. While the lower age limit of
our analysis was higher than that in the trials of hyp-
methylating agents (75 versus 65 years), our cohort repre-
sents highly selected patients who were, despite their
advanced age, deemed fit enough to undergo induction
chemotherapy. Notwhitstanding this obvious limitation,
it is noteworthy that the 3-year OS rate in our cohort was
nominally higher than the rates in both the trials of
hypomethylating agents. In our study, 24 patients (21%)
were still alive 3 years after primary diagnosis, whereas
two patients (1%) in the azacitidine and no patient in the
decitabine trial were still alive at 3 years. Thus, at least a
subset of AML patients may benefit from intensive induc-
tion therapy in terms of sustained remissions and long-
term survival, even at the age of 75 years or above.
Nevertheless, the longer median OS achieved in the trials
of hypomethylating agents suggests that these agents may
be the preferred choice for many elderly patients. 
In clinical practice, the choice between intensive, poten-
tially curative chemotherapy or a palliative therapeutic
approach in old AML patients should be guided by an evi-
dence-based, individualized assessment of the potential
risks (e.g., treatment-related mortality) and benefits of
intensive chemotherapy. In our study, favorable- and
intermediate-risk cytogenetics, IDH1-wildtype status and
good performance status characterized a subset of old
AML patients who may achieve long-term survival after
induction chemotherapy. These patients might be candi-
dates for intensive therapy in the absence of medical con-
traindications. On the other hand, patients with adverse-
risk cytogenetics, IDH1 mutations or poor performance
status did not benefit from intensive induction therapy
and might fare better with alternative strategies such as
hypomethylating agents, or novel targeted agents that
have recently been approved or are currently under devel-
opment.46 In summary, our results show that clinicians
should consider intensive chemotherapy as a therapeutic
option even for selected, very old AML patients.
V.V. Prassek et al.
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